Market Closed -
Japan Exchange
06:30:00 16/01/2026 GMT
5-day change
1st Jan Change
2,397.00 JPY
0.00%
+1.18%
+3.54%
Fuso Pharmaceutical Ordered to Pay 7.47 Billion Yen in Patent Case Over Nalfurafine Tablets Published on 05/28/2025
at 11:04 am BST
MT Newswires
11-10
Fuso Pharmaceutical Industries,Ltd. Announces Second Quarter-End Dividend for the Six Months Ended September 30, 2025, Payable on December 2, 2025
CI
01/08/25
Fuso Pharmaceutical Industries, Ltd. Announces Executive Officer Personnel Appointments, Effective September 1, 2025
CI
25/06/25
Fuso Pharmaceutical Industries, Ltd. Announces Executive Changes
CI
09/06/25
Fuso Pharma Appeals 7.47 Billion Yen Patent Ruling to Japan's Supreme Court
MT
04/06/25
Fuso Pharmaceutical Industries Maintains Fiscal 2025 Forecasts Despite Lawsuit
MT
28/05/25
Fuso Pharmaceutical Ordered to Pay 7.47 Billion Yen in Patent Case Over Nalfurafine Tablets
MT
09/05/25
Fuso Pharmaceutical Industries,Ltd. Announces Dividend for Fiscal Year Ended March 31, 2025, Payable on June 26, 2025; Provides Dividend Guidance for the Second Quarter and Fiscal Year Ending March 31, 2026
CI
09/05/25
Fuso Pharmaceutical Industries,Ltd. Provides Non-Consolidated Earnings Guidance for the First Half and Full Fiscal Year Ending March 31, 2026
CI
06/09/23
Tranche Update on Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback Plan announced on September 5, 2023.
CI
05/09/23
Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback announced on September 5, 2023, has closed with
CI
05/09/23
Fuso Pharmaceutical Industries,Ltd. announces an Equity Buyback for 340,000 shares, representing 3.88% for ¥735 million.
CI
04/09/23
Fuso Pharmaceutical Industries,Ltd. authorizes a Buyback Plan.
CI
19/09/22
Fuso Pharmaceutical Industries,Ltd.(TSE:4538) dropped from S&P Global BMI Index
CI
20/09/21
Fuso Pharmaceutical Industries,Ltd.(TSE:4538) added to S&P Global BMI Index
CI
18/09/17
Fuso Pharmaceutical Industries,Ltd.(TSE:4538) dropped from S&P Global BMI Index
CI
05/09/17
Tranche Update on Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback Plan announced on September 4, 2017.
CI
04/09/17
Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback announced on September 4, 2017 has expired with 154,100 shares, representing 1.72% for ¥421.62 million.
CI
04/09/17
Fuso Pharmaceutical Industries,Ltd. announces an Equity Buyback for 200,000 shares, representing 2.24% for ¥547.2 million.
CI
03/09/17
Fuso Pharmaceutical Industries,Ltd. authorizes a Buyback Plan.
CI
23/10/16
Fuso Pharmaceutical Industries,Ltd. authorizes a Buyback Plan.
CI
23/10/16
Fuso Pharmaceutical Industries,Ltd. announces an Equity Buyback for 866 shares, for ¥2.3 million.
CI
23/10/16
Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback announced on October 24, 2016 has expired.
CI
29/08/16
Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback announced on August 29, 2016 has expired with 1,050,000 shares for ¥271.95 million.
CI
29/08/16
Tranche Update on Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback Plan announced on August 29, 2016.
CI
28/08/16
Fuso Pharmaceutical Industries,Ltd. authorizes a Buyback Plan.
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
4538: Dynamic Chart
Fuso Pharmaceutical Industries, Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceuticals and medical equipment for medical purposes. The Company operates in two business segments. The Pharmaceuticals segment is involved in manufacture and sale of pharmaceutical products, including injectable drugs, which mainly focus on infusion solution, dialysis fluid for artificial kidney, as well as the manufacture and sale of medical equipment and instruments. The Real Estate segment is engaged in the leasing of real estate properties.
More about the company
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
Select your edition
All financial news and data tailored to specific country editions
